Like Bristol Myers’ Opdivo, Merck’s Keytruda is also an anti-PD-1 therapy. It is currently marketed as the standard of care in the frontline treatment of metastatic non-small cell lung cancer ...

Folks with "high-risk" bladder cancers -- tumors that had already invaded nearby muscle -- doubled the time they were ...

Drugs like Bristol Myers Squibb’s Opdivo and Merck’s Keytruda are among the most profitable in the world—Keytruda pulled in $25 billion last year, making it the bestselling drug of 2023.

However, BMS’ setback is further good news for MSD’s Keytruda, which now looks increasingly likely to become the dominant player in NSCLC globally, after Opdivo failed to show efficacy as a ...

Recommended Reading A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology Over the weekend at the European Society for Medical Oncology’s annual meeting in ...

Patients with non-small cell lung cancer saw a reduction in their risk of recurrence or death after surgery when treated with pre- and postsurgical Opdivo. For patients with resectable (removable by ...

The story — and the transformative impact — of Bristol Myers Squibb’s Opdivo and Merck’s Keytruda are well known at this point. Yet the field has also been in a moment of commemoration ...

The company has disclosed a phase 3 trial coded RELATIVITY1093 to evaluate Opdualag—a fixed combination of the PD-1 inhibitor Opdivo and the ... use Merck & Co.’s Keytruda and chemo as the ...

Aethlon Medical, Inc. (Nasdaq: AEMD ), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious ...

Both Bristol Myers Squibb’s Opdivo and Merck & Co.’s Keytruda have shown in separate phase 3 trials that they can extend patients’ disease-free survival time compared with placebo when used ...